Postmenopausal women treated for breast cancer with drugs known as aromatase inhibitors have high rates of sexual problems, which is an important and underestimated issue, according to a new study from Sweden. Nearly three-quarters of these women reported insufficient lubrication, 56 percent had pain during intercourse, half said their sexual interest was low, and 42 percent were dissatisfied with their sex life.
